While adecatumumab (MT201), a fully human anti-EpCAM antibody, showed significant inhibition of MCF-7 breast cancer cell proliferation even without a complement and immune cells [84], in a randomized phase II trial, its monotherapy use in patients with metastatic BC, albeit showing some benefit in patients overexpressing EpCAM, did not lead to tumor regression [85]. Here, EPCAM is linked to breast carcinoma.